secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-04-11T23:59:59+00:00
Accession:  0001641172-25-003889
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA receives Nasdaq minimum equity deficiency notice; equity $2.2M vs $2.5M
----------------------------------------------------------------------------

- Stockholders' equity $2,199,750 as of Dec 31, 2024, below Nasdaq's $2.5M minimum requirement under Rule 5550(b)(1).
- Company has 45 days to submit a compliance plan by May 23, 2025; Nasdaq may grant up to 180-day extension.
- Plans to complete SKNY Pharmaceuticals acquisition with $5M capital infusion to boost equity.
- Also in discussions with strategic investors to strengthen capital position; trading continues uninterrupted.
- Phase 1 trial of Ketamir-2 for neuropathic pain ongoing; first subject dosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225003889/0001641172-25-003889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225003889/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-003889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer